Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2022

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of March 31, 2022 and December 31, 2021 were as follows:


	March 31, 2022		December 31, 2021
Accrued compensation expenses	$	15,625	$	508,343
Accrued research and development		532,322		229,090
Accrued professional fees		78,725		43,102
Other accounts payable and accrued expenses		6,356		63,374
Total	$	633,028	$	843,909